


EV620809164US



ABX-PF1 DIV1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Ilia I. Ouspenski
Group : 1644
Applicants : Douglas Charles Hanson et al.
Application No. : 10/612,497
Confirmation No. : 3552
Filed : July 1, 2003
For : HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

Groton, Connecticut
September 1, 2005

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND DECLARATION OF VAHE BEDIAN

I, VAHE BEDIAN, hereby declare that:

1. I am a Senior Research Fellow in the Department of Exploratory Medicinal Sciences at Pfizer Inc (herein-after "Pfizer"), Assignee of the above-identified application.

2. Hybridoma clones PF1-4-1-1 and PF1-11-2-1 referred to in the August 8, 2005 American Type Culture Collection (ATCC) deposit certificate attached to applicants' Amendment Under 37 C.F.R. § 1.312, filed concurrently herewith, are identical to the hybridoma clones 4.1.1 and 11.2.1 specifically identified in the specification of the above-identified

application. The designations PF1-11-2-1 and PF1-4-1-1 on the ATCC certificate are synonymous with designations 11.2.1 and 4.1.1, respectively, which are used the application.

3. I received clones designated as clone 4.1.1 and clone 11.2.1 from Abgenix, Inc. Under my supervision, the clones were expanded and deposited at the ATCC on July 14, 2005.

4. I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine, or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements may jeopardize the validity of a patent issuing from the above-identified application.

Date: 9/2/05

Vahe Bedian, Ph.D.:

